However, a large number of reports have demonstrated that overexpression of BUB1B was associated with progression and recurrence of pancreatic ductal adenocarcinoma, prostate cancer, hepatocellular carcinoma, and some other cancers19–21. Here, BUB1B is linked to prostate cancer.